OSI 754

Drug Profile

OSI 754

Alternative Names: CP 609754; LNK-754

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OSI Pharmaceuticals
  • Developer AstraZeneca; OSI Pharmaceuticals
  • Class Antineoplastics; Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Farnesyltranstransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Alzheimer's disease; Neurodegenerative disorders
  • Discontinued Bladder cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Alzheimer's-disease in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Neurodegenerative-disorders in USA (PO)
  • 12 Jul 2012 OSI 754 licensed to AstraZeneca worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top